Company Statements

11.13.2024

Amgen Provides Statement on MariTide Phase 1 Data

07.12.2024

Amgen Statement on IRS Notice Related to Horizon Acquisition

04.29.2024

Amgen Update on Patent Litigation Related to Sandoz Denosumab Biosimilar Products

03.01.2024

Update on Change Healthcare Cyberattack

11.16.2023

LUMAKRAS^® (sotorasib) Dose Comparison Study Results

10.05.2023

Amgen Statement on FDA ODAC Meeting

01.06.2023

Statement on FOURIER Analysis Published in BMJ Open

08.16.2022

Statement on Drug Pricing Provisions Included in “Inflation Reduction Act”

06.01.2022

Amgen Statement on Russia/Ukraine

07.12.2021

Amgen Supports Industry Efforts to Address Global Access to COVID-19 Vaccines

11.17.2020

Amgen Proudly Supports PhRMA’s New Principles on Clinical Trial Diversity

07.20.2020

Oklahoma Health Care Authority and Amgen Enter into Value-Based Contract for Enbrel® (etanercept)

05.07.2020

Amgen Comments On the Supreme Court of Japan Ruling On PCSK9 Patent Infringement Litigation

10.18.2019

Amgen Comments on ICER’s Proposed Changes to the 2020 Value Assessment Framework

09.09.2019

Amgen Comments on ICER’s Proposed Methods Adaptations For Assessments of Potential Cures and Other Transformative Therapies

09.04.2019

Amgen Response in Support of the 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias

07.11.2019

Amgen Comments on PCSK9 Patent Litigation in Germany

06.17.2019

Amgen Comments for ICER’s 2020 Value Assessment Framework

06.14.2019

Helping Patients Understand the Price of Their Medicines

05.02.2019

Amgen Reaches Settlement With Coherus in Trade Secrets Case Regarding Pegfilgrastim

04.25.2019

Amgen Reaches Settlement Agreement To Resolve Allegations Related To Patient Assistance Programs

02.21.2019

Amgen’s Comments on ICER’s Value-Based Price Of A Cure Collaborative: Methodological Considerations

02.13.2019

Amgen’s Comments on ICER’s Price Increase Draft Protocol